- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00998101
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
A Phase II Trial of Carboplatin, Ixabepilone and Cetuximab in Chemotherapy Naive Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving chemotherapy together with monoclonal antibodies may be a better way to block cancer growth.
PURPOSE: This phase II trial is studying the side effects and how well giving carboplatin and ixabepilone together with cetuximab works in treating patients with stage III or stage IV non-small cell lung cancer previously untreated with chemotherapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- To estimate the disease-control rate in patients with advanced chemotherapy-naive non-small cell lung cancer after 2 courses of carboplatin, ixabepilone, and cetuximab.
Secondary
- To estimate the progression-free survival of patients treated with this regimen.
- To estimate the overall survival of patients treated with this regimen.
- To estimate the toxicity of this regimen in these patients.
- To determine the potential predictive marker of efficacy of ixabepilone and cetuximab. (exploratory)
- To investigate the prevalence of cetuximab IgE antibody, and the rate of cetuximab hypersensitivity reactions in patients without evidence of cetuximab IgE antibodies.
OUTLINE: This is a multicenter study.
Patients receive carboplatin IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and cetuximab IV over 1-2 hours on days 1, 8 and 15. Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response.
Tumor tissue and blood samples are collected for further analysis.
After completion of study therapy, patients are followed periodically.
Tipo de estudio
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed non-small cell lung cancer
- Chemotherapy-naive
- Stage IIIB disease not amenable to surgery with pleural effusion, pericardial effusion, or not a candidate for chemoradiotherapy
- Stage IV disease
Must have pathology block or unstained slides from initial or subsequent diagnosis
- Diagnosis made via a core biopsy (not a fine-needle aspirate) required
Measurable disease as defined by RECIST guidelines
- For patient who received prior radiotherapy, evaluable disease must be outside of the radiation field, or have new lesions that developed within the radiation field
- Brain metastasis allowed provided it has been treated and determined to be controlled by the treating physician
- No IgE cetuximab antibody
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 8.0 g/dL
- Creatinine < 2.0 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN in the presence of hepatic metastasis)
- Bilirubin ≤ 1.5 times ULN
- Prior malignancy allowed provided the treating physician determines that the patient's life expectancy is best defined by diagnosis of non-small cell lung cancer (NSCLC)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No peripheral neuropathy ≥ grade 2 by NCI CTCAE v. 3.0
No prior severe allergic reaction to any of the following:
- Carboplatin
- Taxane therapy
- Monoclonal antibody
- Hypersensitivity (NCI CTCAE grade3-4) to a drug formulated in Cremophor® EL (polyoxyethylated castor oil)
- No active or uncontrolled infection
No significant history of uncontrolled cardiac disease including, but not limited to, any of the following:
- Uncontrolled hypertension
- Unstable angina
- Myocardial infarction within the past 6 months
- Uncontrolled congestive heart failure
- Cardiomyopathy with decreased ejection fraction
- No underlying interstitial lung disease
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
At least 1 week since prior and no concurrent therapeutic radiotherapy
- Palliative radiotherapy for painful bone lesions allowed
- At least 6 months since prior adjuvant chemotherapy
- No investigational agent(s) within the past 30 days
Not requiring concurrent treatment with any of the following:
- Ketoconazole
- Itraconazole
- Ritonavir
- Amprenavir
- Indinavir
- Nelfinavir
- Delavirdine
- Voriconazole
- No other concurrent chemotherapy or cetuximab
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Disease-control rate after 2 courses of carboplatin, cetuximab, and ixabepilone
Periodo de tiempo: 42 days
|
Disease control rate will be defined as patients experiencing a complete or partial response or stable disease (radiographic response) measured by RECIST criteria.
|
42 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression-free survival
Periodo de tiempo: 2 years
|
Radigoraphic response of measurable disease will be assessed using RECIST critera
|
2 years
|
Overall survival
Periodo de tiempo: 4 years
|
Radigoraphic response of measurable disease will be assessed using RECIST criteria
|
4 years
|
Number of subjects experiencing adverse events
Periodo de tiempo: 1 year
|
Adverse events will be assessed (graded) using CTCAE criteria
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de las vías respiratorias
- Neoplasias
- Enfermedades pulmonares
- Neoplasias por sitio
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Carboplatino
- Cetuximab
Otros números de identificación del estudio
- LCCC 0816
- P30CA016086 (Subvención/contrato del NIH de EE. UU.)
- CDR0000656960 (Otro identificador: PDQ number)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de pulmón
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterReclutamientoCarcinoma de células escamosas de cabeza y cuello | Evaluación de margenPaíses Bajos
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityReclutamientoCáncer colonrectal | Capecitabina | CetuximabPorcelana
-
Eben RosenthalNational Cancer Institute (NCI)TerminadoAdenocarcinoma de páncreasEstados Unidos
-
HiberCell, Inc.TerminadoCáncer colonrectalEstados Unidos, Puerto Rico, Alemania, Francia
-
Merck KGaA, Darmstadt, GermanyTerminadoCáncer colorrectal metastásico no tratado previamenteFrancia, Italia, Polonia, Alemania, Hong Kong, Austria, Brasil, Israel, Grecia, Argentina, Tailandia, Bélgica, Australia, México
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCTerminadoCáncer colorrectal metastásicoAustria
-
Cancer Institute and Hospital, Chinese Academy...Reclutamiento
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminadoCáncer colorrectal metastásicoPaíses Bajos
-
Poitiers University HospitalTerminadoCáncer de colon metastásicoFrancia
-
Copenhagen University Hospital at HerlevDesconocido